Literature DB >> 30661105

A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.

Nadia Solowij1,2, Samantha Broyd3, Lisa-Marie Greenwood3, Hendrika van Hell3, Dave Martelozzo3, Kuna Rueb3, Juanita Todd4, Zheng Liu5,6, Peter Galettis7,5, Jennifer Martin7,5, Robin Murray8, Alison Jones9, Patricia T Michie4, Rodney Croft3.   

Abstract

Access to cannabis and cannabinoid products is increasing worldwide for recreational and medicinal use. Two primary compounds within cannabis plant matter, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), are both psychoactive, but only THC is considered intoxicating. There is significant interest in potential therapeutic properties of these cannabinoids and of CBD in particular. Some research has suggested that CBD may ameliorate adverse effects of THC, but this may be dose dependent as other evidence suggests possible potentiating effects of THC by low doses of CBD. We conducted a randomised placebo controlled trial to examine the acute effects of these compounds alone and in combination when administered by vaporisation to frequent and infrequent cannabis users. Participants (n = 36; 31 male) completed 5 drug conditions spaced one week apart, with the following planned contrasts: placebo vs CBD alone (400 mg); THC alone (8 mg) vs THC combined with low (4 mg) or high (400 mg) doses of CBD. Objective (blind observer ratings) and subjective (self-rated) measures of intoxication were the primary outcomes, with additional indices of intoxication examined. CBD showed some intoxicating properties relative to placebo. Low doses of CBD when combined with THC enhanced, while high doses of CBD reduced the intoxicating effects of THC. The enhancement of intoxication by low-dose CBD was particularly prominent in infrequent cannabis users and was consistent across objective and subjective measures. Most effects were significant at p < .0001. These findings are important to consider in terms of recommended proportions of THC and CBD in cannabis plant matter whether used medicinally or recreationally and have implications for novice or less experienced cannabis users.Trial registration: ISRCTN Registry Identifier: ISRCTN24109245.

Entities:  

Keywords:  Cannabidiol (CBD); Cannabinoids; Cannabis; Intoxication; Synergistic effects; Δ9-Tetrahydrocannabinol (THC)

Mesh:

Substances:

Year:  2019        PMID: 30661105     DOI: 10.1007/s00406-019-00978-2

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  41 in total

1.  THC and CBD blood and brain concentrations following daily administration to adolescent primates.

Authors:  S L Withey; J Bergman; M A Huestis; S R George; B K Madras
Journal:  Drug Alcohol Depend       Date:  2020-06-18       Impact factor: 4.492

2.  Cannabis use and mental health: risks and benefits.

Authors:  Wayne Hall; Eva Hoch; Valentina Lorenzetti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-02       Impact factor: 5.270

3.  Age related differences in cannabis use and subjective effects in a large population-based survey of adult athletes.

Authors:  Joanna S Zeiger; William S Silvers; Edward M Fleegler; Robert S Zeiger
Journal:  J Cannabis Res       Date:  2019-07-29

Review 4.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

Review 5.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

Review 6.  Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence.

Authors:  Madison Wright; Patricia Di Ciano; Bruna Brands
Journal:  Cannabis Cannabinoid Res       Date:  2020-09-02

7.  Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.

Authors:  Reilly R Kayser; Margaret Haney; Marissa Raskin; Caroline Arout; Helen Blair Simpson
Journal:  Depress Anxiety       Date:  2020-05-07       Impact factor: 6.505

8.  Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder.

Authors:  Erin L Martin; Aimee L McRae-Clark
Journal:  Curr Addict Rep       Date:  2020-11-09

9.  Effects of daily Δ9-Tetrahydrocannabinol (THC) alone or combined with cannabidiol (CBD) on cognition-based behavior and activity in adolescent nonhuman primates.

Authors:  Sarah L Withey; Brian D Kangas; Sophia Charles; Andrew B Gumbert; Jessica E Eisold; Susan R George; Jack Bergman; Bertha K Madras
Journal:  Drug Alcohol Depend       Date:  2021-02-17       Impact factor: 4.492

Review 10.  Cannabidiol: pharmacology and therapeutic targets.

Authors:  Stevie C Britch; Shanna Babalonis; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2020-11-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.